Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, Haverty PM, Pandita A, Mohan S, Sampath D, Friedman LS, Ross L, Hampton GM, Amler LC, Shames DS, Lackner MR. Spoerke JM, et al. Among authors: brachmann rk. Clin Cancer Res. 2012 Dec 15;18(24):6771-83. doi: 10.1158/1078-0432.CCR-12-2347. Epub 2012 Nov 7. Clin Cancer Res. 2012. PMID: 23136191
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumors.
Xin Y, Li J, Wu J, Kinard R, Weekes CD, Patnaik A, Lorusso P, Brachmann R, Tong RK, Yan Y, Watts R, Bai S, Hegde PS. Xin Y, et al. Among authors: brachmann r. Clin Cancer Res. 2012 Nov 1;18(21):6040-8. doi: 10.1158/1078-0432.CCR-12-1652. Epub 2012 Sep 7. Clin Cancer Res. 2012. PMID: 22962439 Clinical Trial.
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.
Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC. Jimeno A, et al. Among authors: brachmann rk. Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. doi: 10.1158/1078-0432.CCR-17-2157. Epub 2017 Sep 27. Clin Cancer Res. 2017. PMID: 28954784 Clinical Trial.
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Dotan E, Cardin DB, Lenz HJ, Messersmith W, O'Neil B, Cohen SJ, Denlinger CS, Shahda S, Astsaturov I, Kapoun AM, Brachmann RK, Uttamsingh S, Stagg RJ, Weekes C. Dotan E, et al. Among authors: brachmann rk. Clin Cancer Res. 2020 Oct 15;26(20):5348-5357. doi: 10.1158/1078-0432.CCR-20-0489. Epub 2020 Jul 21. Clin Cancer Res. 2020. PMID: 32694153 Free PMC article. Clinical Trial.
ATP, Cancer and p53.
Dearth LR, Brachmann RK. Dearth LR, et al. Among authors: brachmann rk. Cancer Biol Ther. 2004 Jul;3(7):638-40. doi: 10.4161/cbt.3.7.1095. Epub 2004 Jul 19. Cancer Biol Ther. 2004. PMID: 15326374 Free article. No abstract available.
A global suppressor motif for p53 cancer mutants.
Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK. Baroni TE, et al. Among authors: brachmann rk. Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4930-5. doi: 10.1073/pnas.0401162101. Epub 2004 Mar 22. Proc Natl Acad Sci U S A. 2004. PMID: 15037740 Free PMC article.
A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors.
Patnaik A, LoRusso PM, Messersmith WA, Papadopoulos KP, Gore L, Beeram M, Ramakrishnan V, Kim AH, Beyer JC, Mason Shih L, Darbonne WC, Xin Y, Yu R, Xiang H, Brachmann RK, Weekes CD. Patnaik A, et al. Among authors: brachmann rk. Cancer Chemother Pharmacol. 2014 May;73(5):951-60. doi: 10.1007/s00280-014-2426-8. Epub 2014 Mar 17. Cancer Chemother Pharmacol. 2014. PMID: 24633809 Clinical Trial.
31 results